MME and hydrops fetalis: Currently, we have an approved drug, a dual neprilysin/angiotensin receptor inhibitor, sacubitril/valsartan, for chronic HF, and neprilysin inhibition results in increased endogenous NPs, which is thought to play an important role in improving the prognosis in HF [27].